MedTrace Logo

Propranolol in Severely Burned Children

NCT01957449 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2019-09-24

No results posted yet for this study

Summary

To determine the safety and efficacy of administration of propranolol for reducing heart rate and blood pressure in burn injury.

Conditions

  • Burn

Interventions

DRUG

Propranolol

Propranolol by mouth given daily throughout hospitalization for up to 12 months

DRUG

Placebo

Placebo by mouth given daily throughout hospitalization for up to 12 months.

Sponsors & Collaborators

  • Shriners Hospitals for Children

    collaborator OTHER

  • The University of Texas Medical Branch, Galveston

    lead OTHER

Principal Investigators

  • David N Herndon, MD · University of Texas

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2018-12-31
Completion
2019-04-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01957449 on ClinicalTrials.gov